Osimertinib after lung cancer surgery to slow new lung spots
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent before any study tests or procedures
- You are 30–75 years old
- You had stage I lung adenocarcinoma removed, and there are still “ground-glass” lung spots (GGNs) in at least one other lobe
- Your removed tumor must have an EGFR mutation: either exon 19 deletion or the L858R change
- You recovered well from surgery, are generally doing well day-to-day (WHO performance 0–1), and can be expected to live at least 12 weeks
- You can use effective birth control (and pregnancy is not allowed); if breastfeeding, you must not be
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This study tests whether a targeted therapy pill called osimertinib can work for people whose non-small cell lung cancer came back after they had surgery and completed a course of adjuvant EGFR TKI therapy (like gefitinib or erlotinib). If your cancer has an EGFR mutation and you meet the other health criteria, this trial may offer an additional treatment option.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.